Crosslinked polymeric network and use thereof
A packaging system for the storage of an ophthalmic device includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more crosslinked polymeric networks. The one or more crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan. The aqueous packaging solution has an osmolality of at least about 180 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.
1. A method of preparing a package comprising a storable, sterile ophthalmic device, the method comprising:
(a) immersing an unused ophthalmic device in an aqueous packaging solution comprising one or more crosslinked polymeric networks, wherein the one or more crosslinked polymeric networks comprise a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a first crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan, and wherein the aqueous packaging solution has an osmolality of at least about 180 mOsm/kg and a pH in the range of about 6 to about 9;
(b) packaging the aqueous packaging solution and the unused ophthalmic device in a manner preventing contamination of the unused ophthalmic device by microorganisms; and
(c) sterilizing the packaged aqueous packaging solution and unused ophthalmic device.
2. The method of claim 1 , wherein the first glycosaminoglycan and the second glycosaminoglycan are independently selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, hyaluronan, and hyaluronic acid or a salt thereof.
3. The method of claim 1 , wherein the first glycosaminoglycan is hyaluronic acid and the second glycosaminoglycan is chondroitin sulfate.
4. The method of claim 1 , wherein the first crosslinking agent is a bi- or polyfunctional crosslinking agent comprising two or more functional groups capable of reacting with functional groups of the first glycosaminoglycan and the second glycosaminoglycan.
5. The method of claim 1 , wherein the first crosslinking agent comprises a bis- or polyfunctional crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene (EGDGE), ethylene glycol diglycidyl ether (EGDE), 1,2-ethanediol diglycidyl ether (EDDE), diepoxyoctane, 1,6-hexanediol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ester, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglyglycidyl ether, sorbitol polyglycidyl ether, 1,2,7,8-diepoxyoctane, 1,3-butadiene diepoxide, pentaerythritol tetraglycidyl ether, and a polyepoxide.
6. The method of claim 1 , wherein the reaction product comprises the first glycosaminoglycan crosslinked with the second glycosaminoglycan.
7. The method of claim 6 , wherein the first glycosaminoglycan crosslinked with the second glycosaminoglycan has a weight average molecular weight ranging from about 20,000 to about 6,000,000 Da.
8. The method of claim 1 , wherein the one or more crosslinked polymeric networks further comprise a reaction product of a mixture comprising (a) the reaction product of the first glycosaminoglycan, the second glycosaminoglycan, and the first crosslinking agent, and (b) one or more third glycosaminoglycans.
9. The method of claim 8 , wherein the one or more third glycosaminoglycans are linear hyaluronic acid or linear chondroitin sulfate having a weight average molecular weight ranging from about 10,000 to about 3,000,000 Da.
10. The method of claim 8 , wherein the mixture comprises from about 1 wt. % to about 20 wt. % of the one or more third glycosaminoglycans, based on the total weight of the mixture.
11. The method of claim 1 , wherein the one or more crosslinked polymeric networks are present in the aqueous packaging solution in a concentration of from about 0.01 to about 20% w/w.
12. The method of claim 1 , wherein the one or more crosslinked polymeric networks are present in the aqueous packaging solution in a concentration of from about 0.02 to about 0.1% w/w.
13. The method of claim 1 , wherein the aqueous packaging solution further comprises one or more buffers.
14. The method of claim 13 , wherein the one or more buffers comprise boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and a phosphate buffer.
15. The method of claim 1 , wherein the aqueous packaging solution further comprises one or more tonicity agents.
16. The method of claim 15 , wherein the one or more tonicity agents are present in the aqueous packaging solution in a concentration of from about 0.01 to about 2.5% w/v.
17. The method of claim 1 , wherein the aqueous packaging solution further comprises one or more additional components.
18. The method of claim 17 , wherein the one or more additional components comprise one or more cleaning agents, wetting agents, nutrient agents, sequestering agents, viscosity builders, contact lens conditioning agents, and antioxidants.
19. The method of claim 1 , wherein the unused ophthalmic device is a contact lens.
20. The method of claim 1 , wherein the first glycosaminoglycan is hyaluronic acid or a salt thereof having a weight average molecular weight ranging from about 10,000 to about 200,000, and the second glycosaminoglycan is chondroitin sulfate having a weight average molecular weight ranging from about 10,000 to about 100,000.